Xarelto (Rivaroxaban, BAY59-7939)

DRUG4 trials

Sponsors

Bayer

Conditions

Atrial FibrillationDeep Vein ThrombosisVenous ThromboembolismVenous Thrombosis

Phase 2

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

CompletedNCT00395772

BayerVenous Thromboembolism

Start: 2004-12-31End: 2005-12-31Updated: 2014-10-28

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

CompletedNCT00839163

BayerDeep Vein Thrombosis, Venous Thrombosis

Start: 2004-03-31End: 2005-10-31Updated: 2023-09-07

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

CompletedNCT00973323

BayerAtrial Fibrillation

Start: 2005-09-30End: 2006-03-31Updated: 2014-12-30

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

CompletedNCT00973245

BayerAtrial Fibrillation

Start: 2006-07-31End: 2007-01-31Updated: 2014-12-30

Related Papers

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

2008-07-11235 citations